社交沟通是自闭症谱系障碍药物治疗的一个新兴靶点——关于潜在药物的文献综述
Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents.
作者信息
Baribeau Danielle A, Anagnostou Evdokia
机构信息
University of Toronto, Department of Psychiatry, Toronto, Ontario.
University of Toronto, Department of Pediatrics, Bloorview Research Institute, Toronto, Ontario.
出版信息
J Can Acad Child Adolesc Psychiatry. 2014 Feb;23(1):20-30.
OBJECTIVE
To review the published literature and registered clinical trials on pharmacologic interventions targeting social communication impairment in Autism Spectrum Disorder (ASD).
METHODS
A comprehensive search of several databases (PubMed, MEDLINE, PsycINFO, Clinical trials.gov) was conducted to identify pharmacologic agents that have been, or will be, tested as treatments for social communication impairment in individuals with ASD. Evidence from basic science research supporting rational drug discovery is surveyed.
RESULTS
Data from animal models and early clinical trials suggest that novel and existing compounds, including N-methyl-D-aspartate (NMDA) modulators, γ-aminobutyric acid (GABA) agonists, metabotropic glutamate receptor (mGluR) antagonists and neuropeptides, may enhance social communication/function in ASD. Results from numerous Phase 2 and Phase 3 clinical trials are expected in the near future.
CONCLUSIONS
Recent evidence suggests that social communication may be an appropriate target for pharmacologic manipulation. It is hoped that, in combination with behavioural interventions, novel therapeutics may soon be clinically available to help improve social outcomes.
目的
回顾已发表的关于针对自闭症谱系障碍（ASD）社交沟通障碍的药物干预的文献及注册临床试验。
方法
对多个数据库（PubMed、MEDLINE、PsycINFO、Clinical trials.gov）进行全面检索，以确定已被或即将被测试用于治疗ASD个体社交沟通障碍的药物。调查支持合理药物研发的基础科学研究证据。
结果
动物模型和早期临床试验数据表明，包括N-甲基-D-天冬氨酸（NMDA）调节剂、γ-氨基丁酸（GABA）激动剂、代谢型谷氨酸受体（mGluR）拮抗剂和神经肽在内的新型及现有化合物，可能增强ASD患者的社交沟通/功能。预计在不久的将来会有大量2期和3期临床试验结果。
结论
近期证据表明，社交沟通可能是药物干预的合适靶点。希望结合行为干预，新型疗法可能很快在临床上可用，以帮助改善社交结果。
Zotero 插件